VRAXHealthcare · BiotechnologyVRAX Stock Forecast: Virax Biolabs Group Ltd. Price Predictions for 2026-2027
The 1 Wall Street analysts covering Virax Biolabs Group Ltd. hold a median 12-month price target of $25 — +681.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 15 of 100 as at 20 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
VRAX stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Virax Biolabs Group Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (99): Smaller than most of the companies we track.
Value (4): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
VRAX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on VRAX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +681.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Jan 2026 | HC Wainwright & Co. | Reiterates | Buy | $3.00 → $1.00 |
| 31 Mar 2025 | HC Wainwright & Co. | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VRAX appears on the weeks it earns a place.
VRAX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Virax Biolabs Group Ltd. (VRAX) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.3×
- Price / sales
- 221.3×
- Price / book
- 0.3×
- EV / EBITDA
- 0.7×
Cheaper than 79% of US stocks
Cheaper than 3% of US stocks
Cheaper than 89% of US stocks
Cheaper than 58% of US stocks
- Revenue growth (YoY)
- 684.9%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −35264.9%
- Net margin
- 61.9%
Higher than 98% of US stocks
Higher than 1% of US stocks
Higher than 97% of US stocks
- Return on equity
- −78.6%
- Return on assets
- −54.2%
- Dividend yield
- —
Higher than 16% of US stocks
Higher than 7% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
VRAX vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Virax Biolabs Group Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about VRAX stock
What is the VRAX stock price forecast for 2026-2027?
The 1 Wall Street analysts covering Virax Biolabs Group Ltd. have a median 12-month price target of $25, with estimates ranging from $25 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is VRAX stock a buy right now?
Of the 1 analysts covering Virax Biolabs Group Ltd., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Virax Biolabs Group Ltd. 15 out of 100 across roughly 4,600 US stocks as at 20 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank VRAX?
As at 20 Aug 2026, Virax Biolabs Group Ltd. ranks 15 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (99 of 100).
Will VRAX stock go up?
No one can know that. What the data says: the median 12-month target from 1 analysts implies +681.3% from the last close, and Ticker Nerd's factor model ranks Virax Biolabs Group Ltd. 15 out of 100 as at 20 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the VRAX stock forecast for 2030?
No analyst covering Virax Biolabs Group Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VRAX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $25 over the next 12 months.
How has VRAX stock performed over the past year?
Virax Biolabs Group Ltd. returned -82.7% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Virax Biolabs Group Ltd. do?
Virax Biolabs Group Ltd. is a company specializing in the development and distribution of diagnostic testing kits and related products for the detection and management of viral diseases.
About Virax Biolabs Group Ltd.
Virax Biolabs Group Ltd. is a company specializing in the development and distribution of diagnostic testing kits and related products for the detection and management of viral diseases. The primary purpose of Virax Biolabs is to provide healthcare solutions that aid in the early detection of viral pathogens, a crucial step in preventing the spread of infectious diseases and enabling effective medical intervention. Its products are vital across various sectors including healthcare institutions, government health departments, and research organizations. The company's innovations are particularly significant amid global health crises, offering crucial tools for public health surveillance and response. By serving a diverse market, Virax Biolabs plays a key role in supporting public health initiatives and enhancing the capacity of healthcare systems to manage viral threats effectively. The company's operations underscore the importance of advancing medical diagnostics to safeguard community health and well-being.
CEO Mr. James Foster · 26 employees · United Kingdom · https://viraxbiolabs.com